glucagon has been researched along with metformin in 103 studies
| Studies (glucagon) | Trials (glucagon) | Recent Studies (post-2010) (glucagon) | Studies (metformin) | Trials (metformin) | Recent Studies (post-2010) (metformin) |
|---|---|---|---|---|---|
| 26,039 | 1,498 | 3,054 | 17,793 | 3,176 | 12,526 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (11.65) | 18.7374 |
| 1990's | 11 (10.68) | 18.2507 |
| 2000's | 27 (26.21) | 29.6817 |
| 2010's | 46 (44.66) | 24.3611 |
| 2020's | 7 (6.80) | 2.80 |
| Authors | Studies |
|---|---|
| Coetzee, EJ; Jackson, WP | 1 |
| Giugliano, D; Improta, L; Scognamiglio, G; Torella, R | 1 |
| Binder, D; Giugliano, D; Lefebvre, P; Luyckx, A | 1 |
| Jensen, SL; Kühl, C; Nielsen, OV; Pedersen, J | 1 |
| Berger, W; Heierli, C; Mehnert-Aner, S; Mülly, K; Ritz, R | 1 |
| Carpentier, J; Lefebvre, PJ; Luyckx, AS | 1 |
| Birkeland, KI; Chatzipanagiotou, F; Hanssen, KF; Vaaler, S | 1 |
| Cooper, GJ; Moore, CX | 1 |
| Gawler, DJ; Houslay, MD; Wilson, A | 1 |
| Gawler, D; Houslay, MD; Milligan, G | 1 |
| Disilvio, L; Featherbe, D; Hawa, MI; Jackson, RA; Jaspan, JB; Kurtz, AB; Sim, BM | 1 |
| Branca, S; Coco, R; Damante, G; Del Campo, F; Di Vincenzo, S; Ferlito, S; Fichera, C | 1 |
| Bonora, E; Bosello, O; Butturini, U; Capretti, L; Cigolini, M; Coscelli, C; Zancanaro, C; Zavaroni, I | 1 |
| Ardill, J; Molloy, AM; Tomkin, GH | 1 |
| Biolo, G; Bruttomesso, D; Fongher, C; Inchiostro, S; Panebianco, G; Tessari, P; Tiengo, A; Vedovato, M | 1 |
| Chen, S; Stucki, JW; Ubl, JJ | 1 |
| Khandelwal, RL; Pugazhenthi, S; Yu, B | 1 |
| Ceriello, A; Consoli, G; D'Onofrio, F; De Rosa, N; Giugliano, D; Minei, A; Quatraro, A | 1 |
| Argaud, D; Leverve, XM; Roth, H; Wiernsperger, N | 1 |
| Hamada, Y; Hara, T; Hotta, N; Koh, N; Komori, T; Mori, K; Nakamura, J; Nakashima, E; Naruse, K; Sakakibara, F; Takeuchi, N | 1 |
| Holst, JJ; Nauck, MA; Willms, B | 1 |
| Aiache, JM; Cardot, JM; Saffar, F | 1 |
| Feinglos, MN; Hughes, AT; Luna, B | 1 |
| Bardini, G; Ciani, S; Cremasco, F; Mannucci, E; Mencucci, A; Messeri, G; Ognibene, A; Pierazzuoli, E; Rotella, CM | 1 |
| Holst, JJ; Madsbad, S; Taskiran, M; Toft-Nielsen, MB; Zander, M | 1 |
| Estermann, A; Haag, S; Lutz, TA; Scharrer, E | 1 |
| Banerji, MA; Bastian, W; Castells, S; Taha, DR; Umpaichitra, V | 1 |
| Demuth, HU; Hinke, SA; Hoffmann, T; Kühn-Wache, K; McIntosh, CH; Pederson, RA | 1 |
| Born, J; Fehm, HL; Fruehwald-Schultes, B; Kern, W; Oltmanns, KM; Peters, A; Sopke, S; Toschek, B | 1 |
| Bär, J; Demuth, HU; Hinke, SA; Hoffmann, T; Kühn-Wache, K; Manhart, S; McIntosh, CH; Pederson, RA; Wagner, L; Wermann, M | 1 |
| Demuth, HU; Hinke, SA; McIntosh, CH; Pederson, RA | 1 |
| Inoue, T; Kira, K; Nagakura, T; Saeki, T; Tanaka, I; Yamazaki, K; Yasuda, N | 1 |
| Ashwell, CM; McMurtry, JP | 1 |
| Smith, SA; Tadayyon, M | 1 |
| Brazg, R; D'Alessio, DA; Ehlers, MR; Harley, RE; Kay, HD; Klaff, LJ; Mathisen, AL; Schneider, R | 1 |
| Croom, DK; Lenhard, JM; Minnick, DT | 1 |
| Hamann, A; Morcos, M; Nawroth, P | 1 |
| Floyd, C; Harmon, C; Willoughby, DF | 1 |
| Ahrén, B; Pacini, G | 1 |
| Ahrén, B | 3 |
| Ardill, J; Bell, PM; Duffy, NA; Flatt, PR; Lindsay, JR; McKillop, AM; O'Harte, FP | 1 |
| Bardini, G; Brogi, M; Ciani, S; Cremasco, F; Dicembrini, I; Mannucci, E; Messeri, G; Ognibene, A; Petracca, MG; Pezzatini, A; Rotella, CM; Tesi, F | 1 |
| Keating, GM | 1 |
| Araujo, R; Azevedo, MF; Fernandes-Ferreira, M; Lima, CF; Pereira-Wilson, C | 1 |
| Baptista, T; Beaulieu, S; Contreras, Q; de Mendoza, S; Galeazzi, T; Lacruz, A; Rangel, N; Sandia, I; Vargas, D | 1 |
| Basu, A; Basu, R; Chandramouli, V; Cohen, O; Dicke, B; Landau, BR; Norby, B; Rizza, RA; Shah, P | 2 |
| Debaty, I; Halimi, S; Muller, M; Villaret, L | 1 |
| Carlson, OD; Charles, CP; Chia, CW; Egan, JM; Kim, HS; Kim, W; Melvin, DL; Shin, YK | 1 |
| Ahrén, B; Dejager, S; Ferrannini, E; Foley, JE; Fonseca, VA; Matthews, DR; Zinman, B | 1 |
| Campbell, RK; Cobble, ME; Reid, TS; Shomali, ME | 4 |
| Fernandez-Millan, E; Leclerc, I; Morris, C; Nyirenda, M; Rutter, GA; Sun, G | 1 |
| Cherrington, AD; Donahue, EP; Lacy, B; Printz, RL; Sasaki, N; Shiota, M; Torres, TP; Treadway, JL | 1 |
| Bianchi, L; Bonaventura, A; Carbone, A; Cicero, AF; Derosa, G; Fogari, E; Franzetti, I; Maffioli, P; Querci, F; Romano, D | 1 |
| Cree-Green, M; Mizokami-Stout, K; Nadeau, KJ | 1 |
| Barnea, M; Chapnik, N; Froy, O; Gutman, R; Haviv, L; Madar, Z | 1 |
| Birnbaum, MJ; Chu, Q; Foretz, M; Miller, RA; Viollet, B; Xie, J | 1 |
| Coester, HV; Forst, T; Hincelin-Méry, A; Kapitza, C; Poitiers, F; Ruus, P | 1 |
| Berglund, ED; Cherrington, AD; Habener, JF; Unger, RH | 1 |
| Checklin, HL; Horowitz, M; Jones, KL; Ma, J; Meyer, JH; Rayner, CK; Stevens, JE; Wishart, JM | 1 |
| Ito, R; Matsuda-Nagasumi, K; Mori, I; Negoro, N; Takeuchi, K; Tsujihata, Y | 1 |
| Balas, B; Balena, R; Boldrin, M; Bolli, GB; Charbonnel, B; Gastaldelli, A; Ratner, R; Rosenstock, J | 1 |
| Burris, TP; Fernandez-Ruiz, R; Figueroa, AL; Gomis, R; Marroquí, L; Merino, B; Nadal, A; Quesada, I; Vieira, E | 1 |
| Korbonits, M; Pernicova, I | 1 |
| Anastassiadis, E; Diessel, S; Forst, T; Löffler, A; Pfützner, A | 1 |
| Breitschaft, A; Darstein, C; Golor, G; Hermosillo Reséndiz, K; Hu, K | 1 |
| Abdul-Ghani, MA; Daniele, G; DeFronzo, RA; Eldor, R; Fiorentino, TV; Merovci, A; Norton, L; Perez, Z; Solis-Herrera, C; Tripathy, D; Xiong, J | 1 |
| Ahn, JY; Cho, JY; Cho, YM; Jang, IJ; Kim, JA; Lee, H; Lee, S; Lim, KS; Shin, D; Yu, KS | 1 |
| Apseloff, G; Atiee, G; Bush, MA; Collins, DA; Corsino, L; Feldman, PL; Gillmor, D; McMullen, SL; Morrow, L; Nunez, DJ | 1 |
| Aw, DK; Sinha, RA; Xie, SY; Yen, PM | 1 |
| Bianchi, L; Bonaventura, A; D'Angelo, A; Derosa, G; Fogari, E; Maffioli, P; Romano, D | 1 |
| Hompesch, M; Krentz, AJ; Morrow, L; Norjavaara, E; Petersson, M | 1 |
| Hirshberg, B; Iqbal, N; Lu, J; Sjöstrand, M | 1 |
| Furukawa, A; Ishihara, H; Kosuda, M; Nakazaki, M; Otsuka, Y; Yamaguchi, S | 1 |
| Dela, F; Hansen, M; Helge, JW; Palsøe, MK | 1 |
| Beck-Nielsen, H; Brøsen, K; Christensen, MM; Damkier, P; Hother-Nielsen, O; Højlund, K; Stage, TB | 1 |
| Ahrén, B; Farngren, J; Persson, M | 2 |
| Borg, M; Bound, MJ; Deacon, CF; Horowitz, M; Jones, KL; Little, TJ; Rayner, CK; Wu, T; Zhang, X | 1 |
| de la Peña, A; Del Prato, S; Karanikas, CA; Ludvik, B; Mari, A; Milicevic, Z; Pechtner, V; Shurzinske, L | 1 |
| Bergman, A; Erion, DM; Kazierad, DJ; Lee, DS; Rolph, T; Somayaji, V; Tan, B | 1 |
| Carter, RE; Cobelli, C; Esponda, RR; Johnson, ML; Konopka, AR; Lanza, IR; Nair, KS; Robinson, MM; Schiavon, M; Wondisford, FE | 1 |
| Naito, T; Okamoto, A; Sanada, H; Yokokawa, H | 1 |
| Baranov, O; Deacon, CF; Holst, JJ; Kahle, M; Nauck, MA | 1 |
| Wang, N; Wang, X; Xing, XY; Yang, WY; Yang, ZJ; Zhang, B; Zhang, JP | 1 |
| Bilz, S; Brändle, M; Fournier, JY; Quarella, M; Walser, D | 1 |
| Aston-Mourney, K; Castillo, HA; Ellis, M; Gibert, Y; Wyett, G | 1 |
| Chamarthi, B; Chen, L; Florez, JC; Goldfine, A; Hudson, M; Kaur, V; Littleton, KR; Manning, AK; Merino, J; Srinivasan, S; Thomas, MK | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Bound, MJ; Checklin, HL; Clifton, PM; Grivell, J; Horowitz, M; Jones, KL; Phillips, LK; Rayner, CK; Watson, LE; Wu, T | 1 |
| Li, P; Liu, BL; Liu, Q; Ma, G; Pan, A; Qi, LW; Ying, A; Zhang, WS; Zhang, X | 1 |
| Hamajima, H; Inoue, E; Mieno, E; Miyachi, A; Nagai, Y; Nakagawa, T; Takahashi, M; Tanaka, Y; Yamamoto, Y | 1 |
| Drucker, DJ; Koehler, JA; Matthews, D; Panaro, BL; Sandoval, DA; Song, Y; Yusta, B | 1 |
| Brøsen, K; Bøtker, HE; Dollerup, OL; Frøkiær, J; Hansson, NH; Jespersen, NR; Jessen, N; Larsen, AH; Møller, N; Nørrelund, H; Wiggers, H | 1 |
| Amadid, H; Blond, MB; Bruhn, L; Clemmensen, KKB; Faerch, K; Holst, JJ; Jørgensen, ME; Karstoft, K; Persson, F; Quist, JS; Ried-Larsen, M; Torekov, SS; Vistisen, D; Wewer Albrechtsen, NJ | 1 |
| Li, W; Liu, R; Long, H; Sui, W; Wu, T; Zhang, M; Zhang, Y; Zhao, Y | 1 |
| Conlon, JM; Flatt, PR; Irwin, N; Klempel, N; Thomas, K | 1 |
| Abdelaal, M; Docherty, NG; Elliott, JA; Flatt, PR; Khan, D; Le Roux, CW; Moffett, CR; Naughton, V; Sridhar, A | 1 |
11 review(s) available for glucagon and metformin
| Article | Year |
|---|---|
The use of insulin secretagogues in the treatment of type 2 diabetes.
Topics: Acarbose; Carbamates; Chromans; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Peptide Fragments; Piperidines; Protein Precursors; Risk Factors; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 1999 |
Insulin sensitisation in the treatment of Type 2 diabetes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adrenergic beta-3 Receptor Agonists; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hydroxysteroid Dehydrogenases; Hypoglycemic Agents; Insulin; Insulin Resistance; Islets of Langerhans; Metformin; Peptide Fragments; Protein Precursors; Randomized Controlled Trials as Topic; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Transcription Factors | 2003 |
[Oral diabetes treatment. Which substance is indicated at which time?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Germany; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin; Obesity; Peptide Fragments; Peptides; Practice Guidelines as Topic; Practice Patterns, Physicians'; Treatment Outcome | 2004 |
A lesson in early morning hyperglycemia.
Topics: Blood Glucose Self-Monitoring; Circadian Rhythm; Diabetes Complications; Dose-Response Relationship, Drug; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Metformin; Somatomedins; Time Factors | 2004 |
Islet adaptation to insulin resistance: mechanisms and implications for intervention.
Topics: Adaptation, Physiological; Animals; Blood Glucose; Cholinergic Agonists; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Metformin; Peptide Fragments; Protein Precursors; Sulfonylurea Compounds | 2005 |
DPP-4 inhibitors.
Topics: Adamantane; Animals; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Metformin; Nitriles; Pioglitazone; Protease Inhibitors; Pyrazines; Pyrrolidines; Sitagliptin Phosphate; Substrate Specificity; Thiazolidinediones; Triazoles; Vildagliptin | 2007 |
[New therapies for type 2 diabetes: what place for incretin-based agents and rimonabant compared to the previous ones?].
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Glucagon; Glycoside Hydrolase Inhibitors; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Metabolic Syndrome; Metformin; Piperidines; Pyrazoles; Rimonabant; Safety; Sulfonylurea Compounds; Thiazolidinediones | 2008 |
Insulin resistance in type 2 diabetic youth.
Topics: Adolescent; Body Mass Index; C-Peptide; Child; Diabetes Mellitus, Type 2; Exercise Tolerance; Female; Glucagon; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Male; Metformin; Obesity; Phenotype; Young Adult | 2012 |
Metformin--mode of action and clinical implications for diabetes and cancer.
Topics: AMP-Activated Protein Kinases; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Gluconeogenesis; Humans; Liver; Metformin; Signal Transduction | 2014 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
Glucose-lowering action through targeting islet dysfunction in type 2 diabetes: Focus on dipeptidyl peptidase-4 inhibition.
Topics: Asia, Eastern; Asian People; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Insulin Resistance; Insulin Secretion; Islets of Langerhans; Metformin | 2021 |
39 trial(s) available for glucagon and metformin
| Article | Year |
|---|---|
Effects of metformin on plasma glucose, insulin, FFA, glucagon, growth hormone and cortisol responses to oral glucose in subjects with chemical diabetes.
Topics: Adult; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Tolerance Test; Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Insulin; Male; Metformin; Middle Aged | 1979 |
Effects of metformin treatment on whole-body and splanchnic amino acid turnover in mild type 2 diabetes.
Topics: Amino Acids; Blood Glucose; Carbon Radioisotopes; Diabetes Mellitus, Type 2; Double-Blind Method; Fatty Acids, Nonesterified; Female; Food; Glucagon; Humans; Kinetics; Male; Metformin; Middle Aged; Phenylalanine; Placebos; Proteins; Tritium | 1994 |
Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.
Topics: Blood Glucose; Blood Pressure; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glycated Hemoglobin; Homeostasis; Humans; Islets of Langerhans; Lipids; Male; Metformin; Middle Aged; Obesity; Prospective Studies; Risk Factors; Single-Blind Method | 1993 |
Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus.
Topics: Acarbose; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Metformin; Middle Aged; Peptide Fragments; Protein Precursors; Regression Analysis; Sulfonylurea Compounds; Trisaccharides | 1997 |
Influence of food on glycemia, insulin, C-peptide and glucagon levels in diabetic patients treated with antidiabetic metformin at steady-state.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Diet; Female; Glucagon; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged | 1997 |
Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects.
Topics: Adolescent; Adult; Blood Glucose; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glucose Clamp Technique; Humans; Hypoglycemic Agents; Leptin; Male; Metformin; Middle Aged; Obesity; Peptide Fragments; Peptides | 2001 |
Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Infusions, Parenteral; Insulin; Insulin Secretion; Kinetics; Male; Metformin; Middle Aged; Peptide Fragments; Placebos; Research Design | 2001 |
Beta-cell response to intravenous glucagon in African-American and Hispanic children with type 2 diabetes mellitus.
Topics: Adolescent; Adult; Black or African American; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glycated Hemoglobin; Hispanic or Latino; Humans; Hypoglycemic Agents; Injections, Intravenous; Insulin; Islets of Langerhans; Male; Metformin; Pancreatic Function Tests | 2002 |
Short-term treatment with metformin decreases serum leptin concentration without affecting body weight and body fat content in normal-weight healthy men.
Topics: Adipose Tissue; Adult; Blood Pressure; Body Weight; C-Peptide; Diabetes Mellitus; Glucagon; Humans; Hydrocortisone; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Leptin; Male; Metformin; Obesity; Reference Values | 2002 |
Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Insulin; Metformin; Peptide Fragments; Placebos; Recombinant Proteins; Sulfonylurea Compounds | 2003 |
Insulin counter-regulatory factors, fibrinogen and C-reactive protein during olanzapine administration: effects of the antidiabetic metformin.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; C-Reactive Protein; Double-Blind Method; Female; Fibrinogen; Glucagon; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemic Agents; Insulin; Insulin Resistance; Leptin; Male; Metabolic Syndrome; Metformin; Middle Aged; Olanzapine; Schizophrenia; Sex Factors; Treatment Outcome; Tumor Necrosis Factor-alpha | 2007 |
Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Double-Blind Method; Drug Administration Schedule; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose Clamp Technique; Glycerol; Glycogenolysis; Humans; Hypoglycemic Agents; Infusions, Intravenous; Insulin; Kinetics; Liver; Male; Metformin; Middle Aged; Pioglitazone; Placebos; Thiazolidinediones | 2008 |
Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.
Topics: Area Under Curve; Blood Glucose; Cross-Over Studies; Cyclic AMP; Diabetes Mellitus, Type 2; Diet, Diabetic; Glucagon; Glutaminase; Humans; Hyperglycemia; Hypoglycemic Agents; Immunohistochemistry; Intracellular Signaling Peptides and Proteins; Metformin; Placebos; Postprandial Period; Sulfonylurea Compounds | 2009 |
Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Topics: Adamantane; Diabetes Mellitus, Type 2; Glucagon; Humans; Hypoglycemic Agents; Metformin; Nitriles; Postprandial Period; Pyrrolidines; Sulfonylurea Compounds; Vildagliptin | 2010 |
Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients.
Topics: Blood Glucose; C-Peptide; C-Reactive Protein; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Exercise; Fasting; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Secreting Cells; Italy; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Resistance; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperinsulinism; Hypoglycemic Agents; Incretins; Injections, Subcutaneous; Liraglutide; Male; Metformin; Middle Aged; Peptides | 2013 |
A randomised trial of enteric-coated nutrient pellets to stimulate gastrointestinal peptide release and lower glycaemia in type 2 diabetes.
Topics: Area Under Curve; Blood Glucose; Colon; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hyperglycemia; Ileum; Insulin; Lauric Acids; Male; Metformin; Middle Aged; Tablets, Enteric-Coated; Time Factors | 2013 |
A direct comparison of long- and short-acting GLP-1 receptor agonists (taspoglutide once weekly and exenatide twice daily) on postprandial metabolism after 24 weeks of treatment.
Topics: Adolescent; Adult; Aged; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Exenatide; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Male; Meals; Metformin; Middle Aged; Peptides; Postprandial Period; Receptors, Glucagon; Treatment Outcome; Venoms | 2014 |
Effect of linagliptin compared with glimepiride on postprandial glucose metabolism, islet cell function and vascular function parameters in patients with type 2 diabetes mellitus receiving ongoing metformin treatment.
Topics: Aged; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Islets of Langerhans; Linagliptin; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Postprandial Period; Proinsulin; Purines; Quinazolines; Risk Factors; Sulfonylurea Compounds | 2014 |
Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.
Topics: Adamantane; Adolescent; Adult; Blood Glucose; Cyclohexanes; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Healthy Volunteers; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Liraglutide; Male; Maximum Tolerated Dose; Metformin; Middle Aged; Nateglinide; Nitriles; Phenylalanine; Prognosis; Pyrrolidines; Somatostatin; Vildagliptin; Young Adult | 2014 |
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Topics: Benzhydryl Compounds; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Fasting; Glucagon; Glucose; Glucose Clamp Technique; Glucosides; Humans; Hyperglycemia; Insulin; Male; Metformin; Middle Aged; Muscles; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Time Factors | 2014 |
Pharmacokinetic and pharmacodynamic interaction between gemigliptin and metformin in healthy subjects.
Topics: Adult; Blood Glucose; Cross-Over Studies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Piperidones; Pyrimidines; Young Adult | 2014 |
Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.
Topics: Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Gastrointestinal Hormones; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Insulin; Male; Mesylates; Metformin; Middle Aged; Oxadiazoles; Peptide YY; Prognosis; Pyrazines; Receptors, G-Protein-Coupled; Sitagliptin Phosphate; Triazoles | 2014 |
Comparison of vildagliptin and glimepiride: effects on glycaemic control, fat tolerance and inflammatory markers in people with type 2 diabetes.
Topics: Adamantane; Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dietary Fats; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucose Clamp Technique; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Male; Metformin; Middle Aged; Nitriles; Proinsulin; Pyrrolidines; Sulfonylurea Compounds; Treatment Outcome; Triglycerides; Tumor Necrosis Factor-alpha; Vildagliptin | 2014 |
Effect of exogenously administered glucagon versus spontaneous endogenous counter-regulation on glycaemic recovery from insulin-induced hypoglycaemia in patients with type 2 diabetes treated with a novel glucokinase activator, AZD1656, and metformin.
Topics: Azetidines; Blood Glucose; Body Mass Index; Catecholamines; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Enzyme Activators; Fasting; Female; Glucagon; Glucokinase; Glucose Clamp Technique; Human Growth Hormone; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines | 2014 |
Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Topics: Adamantane; Asian People; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucagon; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period | 2014 |
Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Secreting Cells; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; Insulin Secretion; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Sitagliptin Phosphate | 2015 |
The effect of metformin on glucose homeostasis during moderate exercise.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Exercise; Fatty Acids, Nonesterified; Glucagon; Homeostasis; Hormones; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged | 2015 |
Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial.
Topics: Adult; Blood Glucose; Calorimetry, Indirect; Cross-Over Studies; Fasting; Female; Glucagon; Gluconeogenesis; Glucose; Haplotypes; Humans; Hypoglycemic Agents; Male; Metformin; Organic Cation Transporter 1; Young Adult | 2015 |
Effect of the GLP-1 Receptor Agonist Lixisenatide on Counterregulatory Responses to Hypoglycemia in Subjects With Insulin-Treated Type 2 Diabetes.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hydrocortisone; Hypoglycemia; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Peptides | 2016 |
A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Gastric Emptying; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin; Male; Metformin; Middle Aged; Nitriles; Postprandial Period; Pyrrolidines; Vildagliptin; Whey Proteins | 2016 |
Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Alanine Transaminase; Amino Acids; Aspartate Aminotransferases; beta-Alanine; Blood Glucose; C-Peptide; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazoles; Receptors, Glucagon; Sulfonylurea Compounds | 2016 |
Hyperglucagonemia Mitigates the Effect of Metformin on Glucose Production in Prediabetes.
Topics: Energy Metabolism; Fasting; Glucagon; Glucose; Humans; Insulin; Kinetics; Leucine; Metformin; Prediabetic State; Rest | 2016 |
Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Liraglutide; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Treatment Outcome | 2017 |
Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Aging; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucagon-Secreting Cells; Glucose Clamp Technique; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Male; Meals; Metformin; Risk; Sitagliptin Phosphate; Sweden | 2018 |
A whey/guar "preload" improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: A 12-week, single-blind, randomized, placebo-controlled trial.
Topics: Aged; Blood Glucose; Body Composition; Body Weight; Diabetes Mellitus, Type 2; Diet, Diabetic; Energy Intake; Female; Galactans; Gastric Emptying; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Mannans; Metformin; Middle Aged; Plant Gums; Postprandial Period; Single-Blind Method; Whey Proteins | 2019 |
Effects of anagliptin on plasma glucagon levels and gastric emptying in patients with type 2 diabetes: An exploratory randomized controlled trial versus metformin.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Gastric Emptying; Glucagon; Humans; Hypoglycemic Agents; Male; Mass Spectrometry; Metformin; Middle Aged; Prospective Studies; Pyrimidines; Young Adult | 2019 |
Metformin Lowers Body Weight But Fails to Increase Insulin Sensitivity in Chronic Heart Failure Patients without Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study.
Topics: Aged; Body Composition; Body Weight; Calorimetry, Indirect; Double-Blind Method; Female; Glucagon; Glycated Hemoglobin; Heart Failure; Humans; Insulin Resistance; Male; Metformin; Middle Aged; Mitochondria; Muscle, Skeletal; Oxygen Consumption; Stroke Volume | 2021 |
No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial.
Topics: Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucagon; Glucosides; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Prediabetic State | 2021 |
53 other study(ies) available for glucagon and metformin
| Article | Year |
|---|---|
Diabetes newly diagnosed during pregnancy: A 4-year study at Groote Schuur Hospital.
Topics: Adolescent; Adult; Birth Weight; Black or African American; Black People; Delivery, Obstetric; Diabetes Mellitus; Female; Glucagon; Glucose Tolerance Test; Glyburide; Humans; Infant Mortality; Insulin; Ketones; Labor, Obstetric; Metformin; Pregnancy; Pregnancy in Diabetics; South Africa; White People | 1979 |
Comparative effects of metformin and indanorex in the treatment of reactive hypoglycemia.
Topics: Blood Glucose; Fatty Acids, Nonesterified; Female; Glucagon; Glucose Tolerance Test; Humans; Hydrocortisone; Hypoglycemia; Indans; Indenes; Insulin; Male; Metformin; Time Factors | 1979 |
The effect of metformin on the arginine induced insulin- and glucagon release in pigs.
Topics: Animals; Arginine; Blood Glucose; Glucagon; Insulin; Insulin Secretion; Metformin; Secretory Rate; Swine | 1979 |
[10 cases of lactic acidosis during biguanide therapy (buformin and phenformin)].
Topics: Acidosis; Biguanides; Buformin; Diabetes Mellitus; Glucagon; Humans; Lactates; Liver; Metformin; Phenformin; Shock, Cardiogenic | 1976 |
Influence of metformin on arginine-induced glucagon secretion in human diabetes.
Topics: Adult; Aged; Arginine; Blood Glucose; Body Weight; Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Glucagon; Humans; Insulin; Male; Metformin; Middle Aged | 1975 |
Relationship between blood pressure and in vivo action of insulin in type II (non-insulin-dependent) diabetic subjects.
Topics: Antihypertensive Agents; Blood Pressure; C-Peptide; Diabetes Mellitus, Type 2; Diet, Diabetic; Female; Glucagon; Glucose Clamp Technique; Glyburide; Glycated Hemoglobin; Humans; Hypertension; Infusions, Intravenous; Insulin; Male; Metformin; Middle Aged; Regression Analysis | 1992 |
Co-secretion of amylin and insulin from cultured islet beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic agents.
Topics: Amyloid; Animals; Arginine; Cell Line; Cricetinae; Glucagon; Glucose; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Islet Amyloid Polypeptide; Islets of Langerhans; Kinetics; Metformin; Somatostatin; Tolbutamide | 1991 |
Metformin treatment of lean and obese Zucker rats modulates the ability of glucagon and insulin to regulate hepatocyte adenylate cyclase activity.
Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Animals; Cell Membrane; Enzyme Activation; Glucagon; Insulin; Liver; Male; Metformin; Obesity; Rats; Rats, Zucker | 1989 |
Treatment of streptozotocin-diabetic rats with metformin restores the ability of insulin to inhibit adenylate cyclase activity and demonstrates that insulin does not exert this action through the inhibitory guanine nucleotide regulatory protein Gi.
Topics: Adenylyl Cyclase Inhibitors; Animals; Cell Membrane; Diabetes Mellitus, Experimental; Glucagon; GTP-Binding Proteins; Insulin; Liver; Male; Metformin; Rats; Rats, Inbred Strains | 1988 |
Mechanism of metformin action in non-insulin-dependent diabetes.
Topics: Amino Acids; Blood Glucose; Diabetes Mellitus, Type 2; Glucagon; Glucose; Glucose Tolerance Test; Glycerol; Humans; Insulin; Kinetics; Lactates; Lactic Acid; Liver; Male; Metformin; Middle Aged | 1987 |
Effect of metformin on blood glucose, insulin and C-peptide responses to glucagon in non-insulin dependent diabetics.
Topics: Aged; Blood Glucose; C-Peptide; Diabetes Mellitus; Glucagon; Humans; Insulin; Male; Metformin; Middle Aged; Peptides; Time Factors | 1983 |
Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects.
Topics: Adult; Blood Glucose; C-Peptide; Female; Glucagon; Growth Hormone; Humans; Injections, Intravenous; Insulin; Male; Metformin; Middle Aged | 1984 |
The effect of metformin treatment on gastric acid secretion and gastrointestinal hormone levels in normal subjects.
Topics: Adult; Fasting; Gastric Inhibitory Polypeptide; Gastric Juice; Gastrointestinal Hormones; Glucagon; Humans; Metformin; Vasoactive Intestinal Peptide | 1980 |
Anti-diabetic biguanides inhibit hormone-induced intracellular Ca2+ concentration oscillations in rat hepatocytes.
Topics: Animals; Biguanides; Bucladesine; Calcium; Chlorides; Colforsin; Cyclic AMP; Glucagon; Inositol 1,4,5-Trisphosphate; Insulin; Liver; Male; Manganese Compounds; Metformin; Phenformin; Phenylephrine; Rats; Rats, Wistar; Second Messenger Systems | 1994 |
Effects of metformin on glucose and glucagon regulated gluconeogenesis in cultured normal and diabetic hepatocytes.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Glucagon; Gluconeogenesis; Glucose; Liver; Male; Metformin; Rats; Rats, Sprague-Dawley | 1994 |
Metformin decreases gluconeogenesis by enhancing the pyruvate kinase flux in isolated rat hepatocytes.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Glucagon; Gluconeogenesis; Lactates; Lactic Acid; Liver; Male; Metformin; Perfusion; Pyruvate Kinase; Pyruvates; Pyruvic Acid; Rats; Rats, Wistar | 1993 |
Increased alanine uptake and lipid synthesis from alanine in isolated hepatocytes of Wistar-Kyoto fatty rats: an inhibitory effect of biguanides.
Topics: Aging; Alanine; Animals; Body Weight; Buformin; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Glucagon; Hypoglycemic Agents; Lipids; Liver; Male; Metformin; Rats; Rats, Inbred WKY | 1997 |
Depolarization of the liver cell membrane by metformin.
Topics: Animals; Buffers; Cell Membrane; Glucagon; Gluconeogenesis; Hypoglycemic Agents; In Vitro Techniques; Injections, Intraperitoneal; Liver; Male; Membrane Potentials; Metformin; Mice; Microelectrodes; Rats; Rats, Sprague-Dawley | 2001 |
Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1.
Topics: Animals; Dipeptides; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Humans; Hydrolysis; Hypoglycemic Agents; Kinetics; Metformin; Peptide Fragments; Protein Precursors; Recombinant Proteins; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Substrate Specificity; Swine | 2002 |
On combination therapy of diabetes with metformin and dipeptidyl peptidase IV inhibitors.
Topics: Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Peptide Fragments; Protein Precursors | 2002 |
Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective".
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Metformin; Peptide Fragments; Protease Inhibitors; Protein Precursors | 2002 |
Enhanced secretion of glucagon-like peptide 1 by biguanide compounds.
Topics: Animals; Biguanides; Buformin; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Glucose; Humans; Hypoglycemic Agents; In Vitro Techniques; Male; Metformin; Peptide Fragments; Phenformin; Protease Inhibitors; Protein Precursors; Pyrroles; Rats; Rats, Inbred F344; Valine | 2002 |
Hypoglycemia and reduced feed intake in broiler chickens treated with metformin.
Topics: Animals; Blood Glucose; Body Weight; Chickens; Eating; Fatty Acids, Nonesterified; Glucagon; Insulin; Male; Metformin; Triglycerides | 2003 |
Reduced serum dipeptidyl peptidase-IV after metformin and pioglitazone treatments.
Topics: Aging; Animals; Blood Glucose; Cell Membrane; Dipeptidyl Peptidase 4; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glyburide; Hemoglobins; Hypoglycemic Agents; Insulin; Kidney; Liver; Male; Metformin; Peptide Fragments; Pioglitazone; PPAR gamma; Protein Precursors; Rats; Rats, Zucker; Thiazolidinediones | 2004 |
What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?
Topics: Adenosine Deaminase; Adenosine Deaminase Inhibitors; Animals; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Enzyme Inhibitors; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Glycoproteins; Glycosylation; Humans; Metformin; Mice; Nerve Growth Factors; Neuropeptides; Neurotransmitter Agents; Peptide Fragments; Pituitary Adenylate Cyclase-Activating Polypeptide; Protein Precursors | 2005 |
Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes.
Topics: Administration, Oral; Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Female; Gastric Inhibitory Polypeptide; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Peptide Fragments; Protein Precursors | 2005 |
Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Obesity; Peptide Fragments; Protein Precursors | 2004 |
Exenatide.
Topics: Amino Acid Sequence; Animals; Blood Glucose; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Exenatide; Gastric Emptying; Glucagon; Humans; Hypoglycemic Agents; Injections, Subcutaneous; Insulin; Metformin; Molecular Sequence Data; Peptides; Sulfonylurea Compounds; Venoms | 2005 |
Metformin-like effect of Salvia officinalis (common sage): is it useful in diabetes prevention?
Topics: Animals; Beverages; Blood Glucose; Cells, Cultured; Diabetes Mellitus, Experimental; Female; Glucagon; Glucose; Glucose Tolerance Test; Hepatocytes; Hypoglycemic Agents; Insulin; Male; Metformin; Mice; Mice, Inbred BALB C; Phytotherapy; Plant Extracts; Rats; Rats, Wistar; Salvia officinalis | 2006 |
Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes.
Topics: Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus, Type 2; Fat Emulsions, Intravenous; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose; Glucose Clamp Technique; Glycerol; Heparin; Humans; Insulin; Insulin Resistance; Male; Metformin; Middle Aged; Pioglitazone; Thiazolidinediones | 2008 |
Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Incretins; Insulin; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Receptors, Glucagon; Risk; Sitagliptin Phosphate; Triazoles; Venoms; Weight Loss | 2010 |
Distinguishing among incretin-based therapies. Patient education and self-management.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incretins; Insulin; Insulin Resistance; Liraglutide; Male; Metformin; Middle Aged; Patient Education as Topic; Peptides; Pyrazines; Receptors, Glucagon; Self Care; Sitagliptin Phosphate; Triazoles; Venoms | 2010 |
Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies.
Topics: Adamantane; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Exenatide; Female; Glucagon; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Insulin-Secreting Cells; Liraglutide; Male; Metformin; Middle Aged; Peptides; Pyrazines; Severity of Illness Index; Sitagliptin Phosphate; Time Factors; Triazoles; Venoms | 2010 |
AMP-activated protein kinase regulates glucagon secretion from mouse pancreatic alpha cells.
Topics: Acetyltransferases; Adenosine Triphosphate; AMP-Activated Protein Kinases; Animals; Biphenyl Compounds; Blotting, Western; Calcium; Cell Line; Enzyme Activation; Female; Glucagon; Glucagon-Secreting Cells; Glucose; Hypoglycemic Agents; Immunohistochemistry; Metformin; Mice; Phenformin; Phosphorylation; Pyrones; Thiophenes | 2011 |
Impact of a glycogen phosphorylase inhibitor and metformin on basal and glucagon-stimulated hepatic glucose flux in conscious dogs.
Topics: Animals; Blood Glucose; Dogs; Enzyme Inhibitors; Fasting; Fatty Acids, Nonesterified; Female; Glucagon; Gluconeogenesis; Glucose; Glucose-6-Phosphatase; Glycerol; Glycogen Phosphorylase, Liver Form; Hematocrit; Hypoglycemic Agents; Indoles; Insulin; Lactic Acid; Liver; Liver Glycogen; Male; Metformin; Phenylbutyrates | 2011 |
Metformin affects the circadian clock and metabolic rhythms in a tissue-specific manner.
Topics: Acetyl-CoA Carboxylase; AMP-Activated Protein Kinases; Animals; Basal Metabolism; Circadian Clocks; Glucagon; Leptin; Liver; Metformin; Mice; Motor Activity; Muscle, Skeletal; Organ Specificity; Protein Serine-Threonine Kinases | 2012 |
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP.
Topics: Adenylyl Cyclases; AMP-Activated Protein Kinases; Animals; Biguanides; Cells, Cultured; Cyclic AMP; Cyclic AMP-Dependent Protein Kinases; Diabetes Mellitus, Type 2; Enzyme Activation; Glucagon; Glucose; Hepatocytes; Hypoglycemic Agents; Liver; Metformin; Mice; Phenformin; Phosphorylation; Signal Transduction | 2013 |
Dissecting the actions of widely used diabetes drugs.
Topics: Animals; Cyclic AMP; Diabetes Mellitus; Glucagon; Gluconeogenesis; Humans; Hypoglycemic Agents; Liver; Metformin; Phenformin | 2013 |
TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.
Topics: Animals; Benzofurans; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Glucagon; Glycated Hemoglobin; Homeodomain Proteins; Hypoglycemic Agents; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Proliferating Cell Nuclear Antigen; Rats; Rats, Zucker; Receptors, G-Protein-Coupled; Sulfones; Time Factors; Trans-Activators | 2013 |
Involvement of the clock gene Rev-erb alpha in the regulation of glucagon secretion in pancreatic alpha-cells.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line; Circadian Rhythm; Cytokines; Gene Expression Regulation; Glucagon; Glucagon-Secreting Cells; Glucose; Glycine; Isoquinolines; Metformin; Mice; Nicotinamide Phosphoribosyltransferase; Nuclear Receptor Subfamily 1, Group D, Member 1; RNA, Small Interfering; Signal Transduction; Sirtuin 1; Thiophenes | 2013 |
Differential AMPK phosphorylation by glucagon and metformin regulates insulin signaling in human hepatic cells.
Topics: AMP-Activated Protein Kinases; Cell Line; Cyclic AMP-Dependent Protein Kinases; Gene Knockdown Techniques; Glucagon; Hepatocytes; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Phosphorylation; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction | 2014 |
Differential effects of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide and metformin on pancreatic β-cell and insulin sensitivity during a standardized test meal in patients with type 2 diabetes.
Topics: Adult; Aged; Area Under Curve; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Fasting; Female; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Metformin; Middle Aged; Postprandial Period; Recombinant Fusion Proteins; Treatment Outcome | 2016 |
Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients.
Topics: Adipocytes; Adiponectin; Adult; Benzhydryl Compounds; Biomarkers; Blood Glucose; Body Weight; C-Reactive Protein; Creatinine; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucagon; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1 | 2016 |
Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment.
Topics: Acarbose; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Glucagon; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Patient Education as Topic; Weight Loss | 2017 |
Rapid Onset of Diabetic Ketoacidosis After SGLT2 Inhibition in a Patient With Unrecognized Acromegaly.
Topics: Adenoma; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Fatty Acids, Nonesterified; Gliclazide; Glucagon; Glucosides; Growth Hormone-Secreting Pituitary Adenoma; Humans; Hypoglycemic Agents; Insulin; Ketone Bodies; Male; Metformin; Middle Aged; Severity of Illness Index; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Metformin, beta-cell development, and novel processes following beta-cell ablation in zebrafish.
Topics: Animals; Cell Size; Embryo, Nonmammalian; Embryonic Development; Glucagon; Hypoglycemic Agents; Insulin-Secreting Cells; Metformin; Somatostatin; Zebrafish | 2018 |
Topics: Adult; Aged; Alleles; Blood Glucose; Diabetes Mellitus, Type 2; Female; Genotyping Techniques; Glipizide; Glucagon; Glucagon-Like Peptide 1; Glucose Tolerance Test; Humans; Incretins; Male; Metformin; Middle Aged; Polymorphism, Single Nucleotide; Prospective Studies; Retrospective Studies; Risk Factors; Sulfonylurea Compounds; Transcription Factor 7-Like 2 Protein | 2018 |
Inactivation of NF-κB2 (p52) restrains hepatic glucagon response via preserving PDE4B induction.
Topics: Animals; Blood Glucose; Cyclic AMP; Cyclic Nucleotide Phosphodiesterases, Type 4; Diet, High-Fat; Disease Models, Animal; Fasting; Gene Expression Regulation; Gene Knockdown Techniques; Ginsenosides; Glucagon; Gluconeogenesis; Glucose; Hep G2 Cells; Humans; Liver; Male; Metabolic Diseases; Metformin; Mice; Mice, Inbred C57BL; NF-kappa B p52 Subunit; Promoter Regions, Genetic; Signal Transduction | 2019 |
Intestine-selective reduction of Gcg expression reveals the importance of the distal gut for GLP-1 secretion.
Topics: Animals; Blood Glucose; Colon; Enteroendocrine Cells; Female; Gene Expression; Gene Expression Regulation; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide-2 Receptor; Glucose; Insulin; Intestine, Small; Male; Metformin; Mice; Mice, Knockout; Proglucagon | 2020 |
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Dietary Fats; DNA, Bacterial; Gastrointestinal Microbiome; Glucagon; Glycogen; Hypoglycemic Agents; Insulin; Lacticaseibacillus casei; Liver; Male; Metformin; Mice; Probiotics; Random Allocation; RNA, Bacterial; RNA, Ribosomal, 16S | 2021 |
Alpha-cells and therapy of diabetes: Inhibition, antagonism or death?
Topics: Animals; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glucagon; Glucagon-Like Peptide 1; Glucose; Guanidines; Humans; Hypoglycemic Agents; Insulin; Metformin; Receptors, Glucagon | 2022 |
Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Fenofibrate; Gastric Bypass; Glucagon; Glucagon-Like Peptide 1; Insulin; Liraglutide; Male; Metformin; Obesity; Ramipril; Rats; Rats, Sprague-Dawley; Rats, Zucker; Rosuvastatin Calcium; Somatostatin | 2022 |